Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InflammatoryCompleted with results Location: USA

    Phase 2 Study of inhaled Alpha-1 HC in people with CF , protocol number Grifols T6005-201

    This study took place at multiple care centres across the US. It looked at the safety and tolerability of inhaled Alpha-1 HC administered once a day for three weeks in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      9 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Phase 2 Study of Inhaled Nitric Oxide in People with CF , protocol number NCT02498535

    This study is taking place at multiple care centres across the US. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      35-85%

    • Number of Visits:

      10

    • Length of Participation:

      43 days

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: USA

    Phase 2 study of oral glutathione in children with cystic fibrosis. , protocol number NCT03020719

    This study is taking place at multiple care centres across the USA. It will look at the safety and effectiveness of the oral drug glutathione in children wit cystic fibrosis.

    • Age:

      24 months - 10 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      4

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Vitamin D for enhancing the immune system in people with CF , protocol number TANGPR11A0

    This study evaluated the effect of a single high-dose of vitamin D3 given at the start of a pulmonary exacerbation followed by vitamin D3 maintenance treatment in adults with CF.

    • Age:

      16 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      20% or greater

    • Number of Visits:

      6

    • Length of Participation:

      1 year

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15

    This phase 2 study is taking place at multiple care centers across the US. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Arikace compared to TobiĀ® in people with CF with chronic Pseudomonas aueruginosa infections , protocol number Insmed TR02-108

    This study looked at the effectiveness, safety and tolerability of Arikayce compared to a currently available antibiotic, TOBI (tobramycin inhalation solution). This study was for people with CF with chronic lung infections.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      11

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency , protocol number Axcan UMT20CF07-01

    This study looked at the effectiveness and safety of pancrelipase (ULTRASE MT20) in children who have CF and pancreatic insufficiency.

    • Age:

      7 Years to 11 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      33 days

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Use of Utrase MT 12 Enzymes in Young Children with CF Related Pancreatic Insufficiency , protocol number Axcan UMT12CF08-01

    This study evaluated the safety and effectiveness of pancrelipase (Ultrase MT 12) in young children with CF.

    • Age:

      2 Years to 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      4

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of lumacaftor and ivacaftor in children with CF , protocol number Vertex VX13-809-011a

    This study is taking place at multiple care centers across the U.S. It looked at the safety of lumacaftor in combination with ivacaftor, as well as how the body processes the drugs, in children with CF.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      24 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 3 study of lumacaftor/ivacaftor in children with CF , protocol number Vertex VX15-809-115

    This two-part, open-label study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of lumacaftor/ivacaftor as well as how the body processes the drug, in children with CF.

    • Age:

      2 - 5 Years

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      11

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Displaying results 141-150 (of 168)
     |<  <  8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17  >  >|